BCL2 and non-small cell lung carcinoma: Taratula et al. created a tumor-targeted mesoporous silica nanoparticles (MSN)-based drug delivery system capable of delivering chemotherapeutic drugs such as doxorubicin and cisplatin using two types of siRNA targeted to NSCLC MRP1 and BCL2 mRNA.